PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide.
Solid track record and good value.
Share Price & News
How has PRA Health Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRAH has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: PRAH underperformed the US Life Sciences industry which returned 19.7% over the past year.
Return vs Market: PRAH underperformed the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is PRA Health Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHave PRA Health Sciences, Inc. (NASDAQ:PRAH) Insiders Been Selling Their Stock?
2 months ago | Simply Wall StA Rising Share Price Has Us Looking Closely At PRA Health Sciences, Inc.'s (NASDAQ:PRAH) P/E Ratio
3 months ago | Simply Wall StShareholders Are Thrilled That The PRA Health Sciences (NASDAQ:PRAH) Share Price Increased 200%
Is PRA Health Sciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRAH ($93.45) is trading below our estimate of fair value ($142.34)
Significantly Below Fair Value: PRAH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRAH is good value based on its PE Ratio (24.9x) compared to the US Life Sciences industry average (36.1x).
PE vs Market: PRAH is poor value based on its PE Ratio (24.9x) compared to the US market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: PRAH is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: PRAH is good value based on its PB Ratio (5.4x) compared to the US Life Sciences industry average (5.8x).
How is PRA Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRAH's forecast earnings growth (22.8% per year) is above the savings rate (2.2%).
Earnings vs Market: PRAH's earnings (22.8% per year) are forecast to grow slower than the US market (22.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PRAH's revenue (7.7% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: PRAH's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRAH's Return on Equity is forecast to be high in 3 years time (25.6%)
How has PRA Health Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRAH has high quality earnings.
Growing Profit Margin: PRAH's current net profit margins (7.7%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: PRAH has become profitable over the past 5 years, growing earnings by 37.6% per year.
Accelerating Growth: PRAH's earnings growth over the past year (50.7%) exceeds its 5-year average (37.6% per year).
Earnings vs Industry: PRAH earnings growth over the past year (50.7%) exceeded the Life Sciences industry 9.7%.
Return on Equity
High ROE: Whilst PRAH's Return on Equity (21.63%) is high, this metric is skewed due to their high level of debt.
How is PRA Health Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: PRAH's short term assets ($954.9M) do not cover its short term liabilities ($1.0B).
Long Term Liabilities: PRAH's short term assets ($954.9M) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: PRAH's debt to equity ratio (117.3%) is considered high.
Reducing Debt: PRAH's debt to equity ratio has reduced from 147.9% to 117.3% over the past 5 years.
Debt Coverage: PRAH's debt is well covered by operating cash flow (21%).
Interest Coverage: PRAH's interest payments on its debt are well covered by EBIT (7.5x coverage).
What is PRA Health Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRAH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRAH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRAH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRAH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRAH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Colin Shannon (61yo)
Mr. Colin Shannon has been the Chief Executive Officer at PRA Health Sciences, Inc. since January 1, 2010 and its President since May 2007 and serves as its Chairman of the Board of Directors. Mr. Shannon ...
CEO Compensation Analysis
Compensation vs Market: Colin's total compensation ($USD7.16M) is about average for companies of similar size in the US market ($USD7.36M).
Compensation vs Earnings: Colin's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||2.17yrs||US$2.14m||0.037% $2.2m|
|Executive VP & Chief Scientific Officer||no data||no data||no data|
|Executive VP||no data||no data||0.061% $3.6m|
|Vice President of Legal Affairs||no data||no data||no data|
|Director of Public Relations & Corporate Communications||no data||no data||no data|
|Executive VP and Chief Sales & Marketing Officer||0.50yr||no data||no data|
|Vice President of Human Resources||7.5yrs||no data||no data|
|Senior Vice President of Scientific Affairs||no data||no data||no data|
|Senior VP & Head of Project Management - EAPA||no data||no data||no data|
Experienced Management: PRAH's management team is considered experienced (4.8 years average tenure).
|Independent Director||4.75yrs||US$227.50k||0.015% $881.3k|
|Independent Director||2.92yrs||US$200.00k||0.0081% $481.8k|
|Lead Independent Director||0.92yr||US$170.60k||0.0050% $298.3k|
|Independent Director||5.67yrs||US$220.00k||0.023% $1.4m|
|Independent Director||5.42yrs||US$210.00k||0.011% $642.5k|
Experienced Board: PRAH's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PRAH insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PRA Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PRA Health Sciences, Inc.
- Ticker: PRAH
- Exchange: NasdaqGS
- Founded: 1976
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.955b
- Shares outstanding: 63.72m
- Website: https://prahs.com
Number of Employees
- PRA Health Sciences, Inc.
- 4130 ParkLake Avenue
- Suite 400
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PRAH||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 2014|
|8PH||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2014|
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/11 23:55|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.